Miocamycin is a macrolide antibiotic.[1] It has a spectrum activity similar to that of Erythromycin, but shows higher antimicrobial effect against certain bacteria including Legionella pneumophila (the causative agent of Legionnaires' Disease), Mycoplasma hominis, and Ureaplasma urealyticum.[1] In-vivo studies have further expounded on Miocamycin's efficacy, reporting that the medication is more effective than in-vitro data suggests.[2]
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.054.418 |
Chemical and physical data | |
Formula | C45H71NO17 |
Molar mass | 898.053 g·mol−1 |
3D model (JSmol) | |
Melting point | 220 °C (428 °F) |
Solubility in water | Slightly soluble in water; Soluble in methanol, acetone and chloroform. mg/mL (20 °C) |
| |
| |
(verify) |
References
edit- ^ a b Holliday SM, Faulds D (October 1993). "Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential". Drugs. 46 (4): 720–45. doi:10.2165/00003495-199346040-00008. PMID 7506653. S2CID 195692285.
- ^ Lyseng-Williamson, Katherine A (June 2006). "Miocamycin is an effective option in the treatment of various bacterial infections". Drugs & Therapy Perspectives. 22 (6): 1–6. doi:10.2165/00042310-200622060-00001. ISSN 1172-0360. S2CID 72178165.